How will you decide among the options of either carbo/gem>avelumab or checkpoint monotherapy for cisplatin-ineligible PD-L1 expressing urothelial carcinoma?

The KEYNOTE 052 data as well as other datasets support the idea that there are clearly a subset of previously-untreated cisplatin-ineligible metastatic urothelial cancer patients who receive benefit from front-line immunomonotherapy and can be treated with this approach. Importantly, responding pati...